Equity Profile

TYRA

Tyra Biosciences, Inc.

Health CareBiotechnology$1.9B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and attract investors.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating within the health care sector, Tyra is working on targeted therapies that aim to improve patient outcomes in oncology, an area of significant medical need.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, slightly missing expectations. The stock reacted positively, increasing by 3.79% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Tyra's upcoming earnings report, given its recent stock performance despite ongoing losses.

Bull Case

If Tyra shows significant progress in its clinical trials or better-than-expected EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company fails to provide updates on its pipeline or reports wider losses, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of ongoing clinical trials?

Investors will be keen to understand the timeline and results of clinical trials, as this could significantly impact future revenue potential.

How does the company plan to manage its cash burn moving forward?

Given the ongoing losses, clarity on cash management strategies will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Tyra's clinical trial results, which could be more favorable than anticipated.

Supporting Evidence

The stock has shown resilience despite losses, indicating potential investor confidence.

Options pricing suggests a significant move, which could reflect underlying positive sentiment not fully captured by analysts.

Key Risk

If clinical trial updates are more promising than expected, it could lead to a reevaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Tyra's potential for growth against its current financial challenges, making this earnings report pivotal.

Bull Confirmed If

Positive updates on clinical trial results or a narrower-than-expected EPS loss would signal a bullish outlook.

Bear Confirmed If

Wider losses than anticipated or lack of progress in clinical trials would confirm a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests the stock could rise by around 0.18%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may remain volatile as investors reassess.

Miss

A miss could lead to a decline of about 0.10%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the timeline for upcoming clinical trial results.
2Management's strategy for addressing cash burn and funding future operations.
3Any partnerships or collaborations that could enhance Tyra's market position.
4Insights into competitive landscape changes that may affect Tyra's therapies.
5Updates on regulatory progress for its drug candidates.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and attract investors.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, slightly missing expectations. The stock reacted positively, increasing by 3.79% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Tyra's upcoming earnings report, given its recent stock performance despite ongoing losses.

Bull Case

If Tyra shows significant progress in its clinical trials or better-than-expected EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company fails to provide updates on its pipeline or reports wider losses, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of ongoing clinical trials?

Investors will be keen to understand the timeline and results of clinical trials, as this could significantly impact future revenue potential.

How does the company plan to manage its cash burn moving forward?

Given the ongoing losses, clarity on cash management strategies will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Tyra's clinical trial results, which could be more favorable than anticipated.

Supporting Evidence

The stock has shown resilience despite losses, indicating potential investor confidence.

Options pricing suggests a significant move, which could reflect underlying positive sentiment not fully captured by analysts.

Key Risk

If clinical trial updates are more promising than expected, it could lead to a reevaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Tyra's potential for growth against its current financial challenges, making this earnings report pivotal.

Bull Confirmed If

Positive updates on clinical trial results or a narrower-than-expected EPS loss would signal a bullish outlook.

Bear Confirmed If

Wider losses than anticipated or lack of progress in clinical trials would confirm a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests the stock could rise by around 0.18%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may remain volatile as investors reassess.

Miss

A miss could lead to a decline of about 0.10%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the timeline for upcoming clinical trial results.
2Management's strategy for addressing cash burn and funding future operations.
3Any partnerships or collaborations that could enhance Tyra's market position.
4Insights into competitive landscape changes that may affect Tyra's therapies.
5Updates on regulatory progress for its drug candidates.